New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - fleroxacin 4 mg/ml - solution for infusion - 400 mg - active: fleroxacin 4 mg/ml

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - fleroxacin 200mg - tablet - 200 mg - active: fleroxacin 200mg

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - fleroxacin 400mg - tablet - 400 mg - active: fleroxacin 400mg

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

fleroxacin 200mg, 400mg

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

fleroxacin 400mg/100ml

United States - English - NLM (National Library of Medicine)

medi-physics inc. dba ge healthcare. - indium in-111 oxyquinoline (unii: lgx9ol562t) (indium cation in-111 - unii:wjz06c0h8l) - indium cation in-111 1 ug in 1 ml - indium in 111 oxyquinoline solution is indicated for radiolabeling autologous leukocytes. indium in 111 oxyquinoline labeled leukocytes may be used as an adjunct in the detection of inflammatory processes to which leukocytes migrate, such as those associated with abscesses or other infection, following reinjection and detection by appropriate imaging procedures. the degree of accuracy may vary with labeling techniques and with the size, location and nature of the inflammatory process. indium in 111 oxyquinoline labeled leukocyte imaging is not the preferred technique for the initial evaluation of patients with a high clinical probability of an abscess in a known location. ultrasound or computed tomography may provide a better anatomical delineation of the infectious process and information may be obtained more quickly than with labeled leukocytes. if localization by these techniques is successful, labeled leukocytes should not be used as a confirmatory procedure. if localization or diagnosis by these methods fails or is ambiguous, indium in 111 oxyquinoline labeled leukocyte imaging may be appropriate. none known.

United States - English - NLM (National Library of Medicine)

bwxt medical ltd. - indium in-111 oxyquinoline (unii: lgx9ol562t) (indium cation in-111 - unii:wjz06c0h8l) - indium in 111 oxyquinoline is indicated for radiolabeling autologous leukocytes. indium in 111 oxyquinoline labeled leukocytes may be used as an adjunct in the detection of inflammatory processes to which leukocytes migrate, such as those associated with abscesses or other infection, following reinjection and detection by appropriate imaging procedures. the degree of accuracy may vary with labeling techniques and with the size, location and nature of the inflammatory process. indium in 111 oxyquinoline labeled leukocyte imaging is not the preferred technique for the initial evaluation of patients with a high clinical probability of an abscess in a known location. ultrasound or computed tomography may provide a better anatomical delineation of the infectious process and information may be obtained more quickly than with labeled leukocytes. if localization by these techniques is successful, labeled leukocytes should not be used as a confirmatory procedure. if localization or diagnosis by these methods fails or

United States - English - NLM (National Library of Medicine)

anazaohealth corporation - indium in-111 oxyquinoline (unii: lgx9ol562t) (indium in-111 oxyquinoline - unii:lgx9ol562t) - indium in-111 oxyquinoline 2 mci in 1 ml - this preparation is supplied as a sterile, non-pyrogenic, isotonic aqueous solution with a ph range of 6.5 to 7.5 and is not for direct injection. each milliliter contains 2 mci at calibration time, 50μg oxyquinoline, 100μg polysorbate 80, and 6 mg of hepes (n-2-hydroxyethyl-piperazine-n’-2-ethane sulfonic acid) buffer in 0.75% sodium chloride solution. it is intended for single use only and contains no bacteriostatic agent.

United States - English - NLM (National Library of Medicine)

coopersurgical, inc. - oxyquinoline sulfate (unii: 61vug75y3p) (oxyquinoline - unii:5utx5635hp), sodium lauryl sulfate (unii: 368gb5141j) (lauryl sulfate - unii:diq16uc154) - 1. to help restore and maintain normal vaginal acidity. 2.   to coat walls of vagina with a lubricating film that may help reduce odor-causing bacteria, since bacteria can flourish in abnormal vaginal ph. 1. unscrew cap from tube 2. pierce end of tube with top of cap (a small amount of trimo-san may escape when top of tube is pierced). 3. attach threaded end of the universal applicator to trimo-san tube (see picture 1). 4. while holding the universal applicator, squeeze the tube from the bottom until trimo-san reaches the specified dosage level (see picture 2). 5. detach the universal applicator from the tube. gently insert the universal applicator approximately ½ inch into the vagina.     press in the plunger of the universal applicator to dispense the gel. keep the plunger pressed until the universal applicator is removed from the vagina. note: for those wearing an inflat-o-ball or cube pessary, remove pessary per physician’s instruction before application of trimo-san. 6. clean the universal applic

United States - English - NLM (National Library of Medicine)

denison pharmaceuticals, llc - oxyquinoline sulfate (unii: 61vug75y3p) (oxyquinoline - unii:5utx5635hp), sodium lauryl sulfate (unii: 368gb5141j) (lauryl sulfate - unii:diq16uc154) -